Publications

These are publications from work undertaken by Frontier Science (Scotland).

H A Azim Jr;  D Agbor-Tarh; I Bradbury; P Dinh; J Baselga; S Di Cosimo; J G Greger; I Smith; C Jackisch; S Kim; B Aktas; C S Huang; P Vuylsteke; R K Hsieh; L Dreosti; H. Eidtmann; M. Piccart; E. de Azambuja;  2013

Pattern of Rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial

Journal of Clinical Oncology,  Volume 31, Issue 36, Pages 4504-4511, doi:10.1200/JCO.2013.50.9448


B C Pestalozzi;  E Holmes; E. de Azambuja; O Metzger-Filho; L Hogge; M Scullion; I Lang; A Wardley; M Lichinitser; R I Lopez-Sanchez; V Muller; D Dodwell; RD Gelber; M Piccart-Gebhart; D Cameron;  2013

CNS Relapses in Patients with HER2-positive early breast cancer who have and who have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

The Lancet Oncology,  Volume 14, Issue 3, Pages 244-248, doi:10.1016/S1470-2045(13)70017-2


A H Partridge;  S Gelber; M Piccart-Gebhart; F Focant; M Scullion; E Holmes; E P Winer; RD Gelber;  2013

Effect of Age on Breast Cancer outcomes in Women with HER-2 positive Breast Cancer: Results from a Herception Adjuvant Trial

Journal of Clinical Oncology,  Volume 31, Issue 21, Pages 2692-2698, doi:10.1200/JCO.2012.44.1956


S Loibl;  I J Majewski; V Guarneri; V Nekljudova; E Holmes; E Bria; C Denkert; C Schem; C Sotiriou; S Loi; M Untch; P Conte; R Bernards; M. Piccart; G von Minckwitz; J Baselga;  2016

PIK3CA Mutations are Associated with reduced pathological complete response rates in primary HER2-positive breast cancer-pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of Oncology,  Volume 27, Issue 8, Pages 1519-1525, doi:10.1093/annonc/mdw197


P Nuciforo;  C Aura; E Holmes; L Prudkin; J Jimenez; P Martinez; H Ameels; L de la Pena; CE Ellis; H. Eidtmann; M. Piccart; M Scaltriti; J Baselga;  2015

Benefit to Neoadjuvant anti-Human Epidermal Growth Factor Receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) Status

Annals of Oncology,  Volume 26, Issue 7, Pages 1494-1500, doi:10.1093/annonc/mdv175


I J Majewski;  P Nuciforo; L Mittempergher; A J Bosma; H. Eidtmann; E Holmes; C Sotiriou; D Fumagalli; J Jimenez; C Aura; L Prudkin; M C Diaz-Delgado; L de la Pena; S Loi; C Ellis; N Schultz; E. de Azambuja; N Harbeck; M Piccart-Gebhart; R Bernards; J Baselga;  2015

PIK3CA Mutations are Associated with decreased benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2- Targeted Therapies in Breast Cancer

Journal of Clinical Oncology,  Volume 33, Issue 12, Pages 1334-1339, doi:10.1200/JCO.2014.55.2158


G Gebhart;  C Gamez; E Holmes; J Robles; M Cortes; M E de Azambuja; K Fauria; V Van Dooren; G Aktan; M Coccia-Portugal; S Kim; P Vuylsteke; H Cure; H. Eidtmann; J Baselga; M. Piccart; P Flamen; S Di Cosimo;  2013

18F-FDG-PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

Journal of Nuclear Medicine,  Volume 54, Issue 11, Pages 1862-1868, doi:10.2967/jnumed.112.119271


M Piccart-Gebhart;  E Holmes; J Baselga; E. de Azambuja; AC Dueck; G Viale; J A Zujewski; A Goldhirsch; A Armour; KI Pritchard; A E McCollough; S Dolci; E McFadden; A P Holmes; L Tonghua; H. Eidtmann; P Dinh; S. Di Cosimo; N Harbeck; S Tjulandin; Y H Im; C S Huang; V Dieras;  2016

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-positive Breast Cancer: Results from the Randomized Phase III Adjuvant Lapatinib and/ or Trastuzumab Treatment Optimization Trial

Journal of Clinical Oncology,  Volume 34, Issue 10, Pages 1034-1042, doi:10.1200/JCO.2015.62.1797


E. de Azambuja;  A P Holmes; M Piccart-Gebhart; E Holmes; S. Di Cosimo; R F Swaby; M Untch; C Jackisch; I Lang; I Smith; F Boyle; B Xu; C H Barrios; EA Perez; H A Azim Jr; S Kuemmel; C S Huang; P Vuylsteke; R K Hsieh; V Gorbunova; A Eniu; L Dreosti; N Tavartkiladze;  2014

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomized, open-label, multicentre, phase 3 trial and their association with pathological complete response

The Lancet Oncology,  Volume 15, Issue 10, Pages 1137-1146, doi:10.1016/S1470-2045(14)70320-1


M Scaltriti;  P Nuciforo; I Bradbury; J Sperinde; D Agbor-Tarh; C Campbell; A Chenna; J Winslow; V Serra; JL Parra; L Prudkin; J Jimenez; C Aura;  2015

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab

Clinical Cancer Research,  Volume 21, Issue 3, Pages 569-76, doi:10.1158/1078-0432.CCR-14-1824